6:06 AM
 | 
Sep 14, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Merck's Zerbaxa non-inferior to meropenem in Phase III for bacterial pneumonia

Merck & Co. Inc. (NYSE:MRK) said Zerbaxa ceftolozane/tazobactam met the primary endpoints in the Phase III ASPECT-NP trial to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Zerbaxa was non-inferior to meropenem in all-cause mortality at day 28 and in clinical cure rate at the test-of-cure (TOC) visit 7-14 days after the end of...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >